Alendronate Related Published Studies
Well-designed clinical trials related to Alendronate
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. [2009.08]
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. [2009.06]
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. [2009.06]
Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. [2009.05]
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. [2009.05]
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. [2009.04]
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. [2009.04]
Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. [2009.02.15]
Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study. [2009.02]
Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. [2009.02]
Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. [2009.01]
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. [2009.01]
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. [2009.01]
The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. [2009]
Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. [2009]
Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women. [2009]
Alendronate is effective to treat bone loss in renal transplantation recipients. [2008.12]
A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. [2008.12]
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.12]
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. [2008.12]
Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. [2008.11]
Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. [2008.11]
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). [2008.10]
The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. [2008.10]
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. [2008.09.20]
[Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases] [2008.07.15]
The effects of systemic alendronate with or without intraalveolar collagen sponges on postextractive bone resorption: a single masked randomized clinical trial. [2008.07]
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. [2008.07]
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. [2008.07]
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. [2008.06.20]
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). [2008.05]
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. [2008.04]
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. [2008.02.29]
Alendronate decreases TRACP 5b activity in osteoarthritic bone. [2008.01.23]
Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. [2008.01]
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. [2008]
Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K(2) in postmenopausal women. [2008]
Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. [2008]
Well-designed clinical trials possibly related to Alendronate
Effects of teriparatide retreatment in osteoporotic men and women. [2009.07]
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. [2009.06.23]
Giant osteoclast formation and long-term oral bisphosphonate therapy. [2009.01.01]
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. [2009]
Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. [2008.10]
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. [2008.08]
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. [2008.08]
Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: A single-center, single-blind, six-period crossover study in healthy female subjects. [2008.05]
[Influence of adjuvant pain medication on quality of life in the treatment of postmenopausal osteoporosis] [2008.05]
Prevention of bone loss after withdrawal of tamoxifen. [2008.03]
Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis. [2008.03]
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy : a retrospective study. [2008]
|
